Clinical trial
Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase…
NCT00114959 · ChemGenex Pharmaceuticals, Industry · Terminated
Key facts
| NCT number | NCT00114959 |
|---|---|
| Title | Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML) |
| Official title | A Phase II Open-Label Study of the Intravenous Administration of Homoharringtonine (CGX-635) Combined With the Oral Administration of Gleevec in the Treatment of Patients With Chronic Myeloid Leukemia (CML) in Chronic, Accelerated, and Blast Phase |
| Lead sponsor | ChemGenex Pharmaceuticals, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Myeloid Leukemia, Chronic, Accelerated-Phase, Blast Phase, Chronic-Phase |
| Intervention type | Drug |
| Interventions | Homoharringtonine, Imatinib Mesylate |
| Enrollment | 15 |
| Start date | Oct 1, 2005 |
| Primary completion | Jun 1, 2008 |
| Completion | Mar 1, 2009 |
| First posted | Jun 21, 2005 |
| Last update posted | Jan 15, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: